文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对结直肠癌，具有新抗原反应性的 T 细胞表现出有效的抗肿瘤活性。

Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.

机构信息

Department of Gastrointestinal Surgery, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

出版信息

Hum Vaccin Immunother. 2022 Dec 31;18(1):1-11. doi: 10.1080/21645515.2021.1891814. Epub 2021 Mar 9.

DOI:10.1080/21645515.2021.1891814
PMID:33689574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8920255/
Abstract

Neoantigens play a crucial role in cancer immunotherapy. However, the effectiveness and safety of neoantigen-based immunotherapies in patients with colorectal cancer (CRC), particularly in the Chinese population, have not been well studied. This study explored the feasibility and effectiveness of neoantigens in the treatment of CRC. Whole-exome sequencing (WES) and transcriptome sequencing were used to identify somatic mutations, RNA expression, and human leukocyte antigen (HLA) alleles. Neoantigen candidates were predicted, and immunogenicity was assessed. The neoantigens TSHZ3-L523P, RARA-R83H, TP53-R248W, EYA2-V333I, and NRAS-G12D from Patient 4 (PW4); TASP1-P161L, RAP1GAP-S215R, MOSPD1-V63I, and NAV2-D1973N from Patient 10 (PW10); and HAVCR2-F39V, SEC11A-R11L, SMPDL3B-T452M, LRFN3-R118Q, and ULK1-S248L from Patient 11 (HLA-A0201PW11) induced a heightened neoantigen-reactive T cell (NRT) response as compared with the controls in peripheral blood lymphocytes (PBLs) isolated from patients with CRC. In addition, we identified neoantigen-containing peptides SEC11A-R11L and ULK1-S248L from HLA-A0201PW11, which more effectively elicited specific CTL responses than the corresponding native peptides in PBLs isolated from HLA-A0201PW11 as well as in HLA-A2.1/K transgenic mice. Importantly, adoptive transfer of NRTs induced by vaccination with two mutant peptides could effectively inhibit tumor growth in tumor-bearing mouse models. These data indicate that neoantigen-containing peptides with high immunogenicity represent promising candidates for peptide-mediated personalized therapy. CRC: colorectal cancer; DCs: dendritic cells; ELISPOT: enzyme-linked immunosorbent spot; E:T: effector:target; HLA: human leukocyte antigen; MHC: major histocompatibility complex; Mut: mutant type; NGS: next-generation sequencing; NRTs: neoantigen-reactive T cells; PBMCs: peripheral blood mononuclear cells; STR: short tandem repeat; PBLs: peripheral blood lymphocytes; PBS: phosphate-buffered saline; PD-1: programmed cell death protein 1; TILs: tumor-infiltrating lymphocytes; RNA-seq: RNA sequencing; Tg: transgenic; TMGs: tandem minigenes; WES: whole-exome sequencing; WT: wild-type.

摘要

新抗原在癌症免疫治疗中发挥着关键作用。然而，基于新抗原的免疫疗法在结直肠癌（CRC）患者中的有效性和安全性，特别是在中国人群中的疗效，尚未得到充分研究。本研究探索了新抗原在 CRC 治疗中的可行性和有效性。我们使用全外显子组测序（WES）和转录组测序来鉴定体细胞突变、RNA 表达和人类白细胞抗原（HLA）等位基因。预测了新抗原候选物，并评估了其免疫原性。来自患者 4（PW4）的 TSHZ3-L523P、RARA-R83H、TP53-R248W、EYA2-V333I 和 NRAS-G12D；来自患者 10（PW10）的 TASP1-P161L、RAP1GAP-S215R、MOSPD1-V63I 和 NAV2-D1973N；以及来自 HLA-A0201PW11 的 HAVCR2-F39V、SEC11A-R11L、SMPDL3B-T452M、LRFN3-R118Q 和 ULK1-S248L，与从 CRC 患者中分离的外周血淋巴细胞（PBLs）中的对照相比，诱导了更高的新抗原反应性 T 细胞（NRT）反应。此外，我们鉴定了来自 HLA-A0201PW11 的新抗原肽 SEC11A-R11L 和 ULK1-S248L，与来自 HLA-A0201PW11 以及 HLA-A2.1/K 转基因小鼠的 PBLs 中相应的天然肽相比，这些肽能更有效地引发特异性 CTL 反应。重要的是，接种两种突变肽疫苗诱导的 NRT 转移可有效抑制荷瘤小鼠模型中的肿瘤生长。这些数据表明，具有高免疫原性的含新抗原肽是肽介导的个体化治疗的有前途的候选物。CRC：结直肠癌；DCs：树突状细胞；ELISPOT：酶联免疫斑点；E:T：效应物：靶标；HLA：人类白细胞抗原；MHC：主要组织相容性复合体；Mut：突变型；NGS：下一代测序；NRTs：新抗原反应性 T 细胞；PBMCs：外周血单核细胞；STR：短串联重复；PBLs：外周血淋巴细胞；PBS：磷酸盐缓冲盐水；PD-1：程序性细胞死亡蛋白 1；TILs：肿瘤浸润淋巴细胞；RNA-seq：RNA 测序；Tg：转基因；TMGs：串联 minigenes；WES：全外显子组测序；WT：野生型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/ce09ae2c13e1/KHVI_A_1891814_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/33c59a8f1e05/KHVI_A_1891814_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/9406795b0f9a/KHVI_A_1891814_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/54c6477c9c60/KHVI_A_1891814_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/7f3ee65afae2/KHVI_A_1891814_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/ce09ae2c13e1/KHVI_A_1891814_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/33c59a8f1e05/KHVI_A_1891814_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/9406795b0f9a/KHVI_A_1891814_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/54c6477c9c60/KHVI_A_1891814_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/7f3ee65afae2/KHVI_A_1891814_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a81a/8920255/ce09ae2c13e1/KHVI_A_1891814_F0005_OC.jpg

相似文献

[1]
Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.

Hum Vaccin Immunother. 2022-12-31

[2]
Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.

Front Oncol. 2021-4-13

[3]
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.

Genome Med. 2019-12-30

[4]
Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.

Cancer Sci. 2022-4

[5]
Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.

JCI Insight. 2021-7-22

[6]
Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.

J Immunother Cancer. 2023-4

[7]
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.

Immunol Invest. 2021-7

[8]
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.

Oncoimmunology. 2021-5-25

[9]
Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.

Biomed Pharmacother. 2023-12

[10]
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.

J Immunother Cancer. 2022-9

引用本文的文献

[1]
Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices.

Med Oncol. 2025-5-31

[2]
RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in bladder cancer.

Discov Oncol. 2025-5-22

[3]
Adoptive immune cell therapy for colorectal cancer.

Front Immunol. 2025-4-1

[4]
The T cell receptor β chain repertoire of tumor infiltrating lymphocytes improves neoantigen prediction and prioritization.

Elife. 2024-10-28

[5]
Deciphering MOSPD1's impact on breast cancer progression and therapeutic response.

Biol Direct. 2024-10-5

[6]
SMPDL3B contributes to gastric adenocarcinoma cells progression by promoting the infiltration of M2 macrophages.

Turk J Med Sci. 2023

[7]
Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma.

Sci Rep. 2024-3-26

[8]
Colorectal Cancer Immunotherapy: State of the Art and Future Directions.

Gastro Hep Adv. 2023

[9]
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.

Biomark Res. 2023-12-1

[10]
Neo-Antigen-Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach.

Glob Chall. 2023-10-17

本文引用的文献

[1]
Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets.

Biomed Res Int. 2020

[2]
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.

Genome Med. 2019-12-30

[3]
Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis.

BMC Med Genomics. 2019-7-3

[4]
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Cancer Discov. 2019-6-4

[5]
Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer.

J Immunol Res. 2019-3-3

[6]
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.

J Clin Invest. 2019-3-5

[7]
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Nature. 2018-12-19

[8]
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.

Nat Med. 2018-6-4

[9]
An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.

Front Immunol. 2017-11-15

[10]
An immunogenic personal neoantigen vaccine for patients with melanoma.

Nature. 2017-7-13

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索